Cargando…
Bisphosphonates and atypical subtrochanteric fractures of the femur
OBJECTIVES: Bisphosphonates are widely used as first-line treatment for primary and secondary prevention of fragility fractures. Whilst they have proved effective in this role, there is growing concern over their long-term use, with much evidence linking bisphosphonate-related suppression of bone re...
Autores principales: | Kharwadkar, N., Mayne, B., Lawrence, J. E., Khanduja, V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376663/ https://www.ncbi.nlm.nih.gov/pubmed/28288986 http://dx.doi.org/10.1302/2046-3758.63.BJR-2016-0125.R1 |
Ejemplares similares
-
Subtrochanteric femur fractures: current review of management
por: Garrison, Ian, et al.
Publicado: (2021) -
Bisphosphonates-induced Atypical Subtrochanteric Fracture Femur: A Case Report
por: Yadav, Siddhart, et al.
Publicado: (2018) -
Bisphosphonates and Atypical Fractures of Femur
por: Yli-Kyyny, Tero
Publicado: (2011) -
Oral Bisphosphonates and Risk of Subtrochanteric or Diaphyseal Femur Fractures in a Population-Based Cohort
por: Kim, Seo Young, et al.
Publicado: (2011) -
Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures
por: Fukuda, Fumio, et al.
Publicado: (2014)